File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Discovery of a Novel Specific Inhibitor Targeting Influenza A Virus Nucleoprotein with Pleiotropic Inhibitory Effects on Various Steps of the Viral Life Cycle

TitleDiscovery of a Novel Specific Inhibitor Targeting Influenza A Virus Nucleoprotein with Pleiotropic Inhibitory Effects on Various Steps of the Viral Life Cycle
Authors
Keywordsinfluenza
nucleoprotein
small-molecule inhibitor
Issue Date2021
PublisherAmerican Society for Microbiology. The Journal's web site is located at http://jvi.asm.org/
Citation
Journal of Virology, 2021, v. 95 n. 9, p. article no. e01432-20 How to Cite?
AbstractInfluenza A viruses (IAVs) continue to pose an imminent threat to humans due to annual influenza epidemic outbreaks and episodic pandemics with high mortality rates. In this context, the suboptimal vaccine coverage and efficacy, coupled with recurrent events of viral resistance against a very limited antiviral portfolio, emphasize an urgent need for new additional prophylactic and therapeutic options, including new antiviral targets and drugs with new mechanisms of action to prevent and treat influenza virus infection. Here, we characterized a novel influenza A virus nucleoprotein (NP) inhibitor, FA-6005, that inhibited a broad spectrum of human pandemic and seasonal influenza A and B viruses in vitro and protects mice against lethal influenza A virus challenge. The small molecule FA-6005 targeted a conserved NP I41 domain and acted as a potentially broad, multimechanistic anti-influenza virus therapeutic since FA-6005 suppressed influenza virus replication and perturbed intracellular trafficking of viral ribonucleoproteins (vRNPs) from early to late stages. Cocrystal structures of the NP/FA-6005 complex reconciled well with concurrent mutational studies. This study provides the first line of direct evidence suggesting that the newly identified NP I41 pocket is an attractive target for drug development that inhibits multiple functions of NP. Our results also highlight FA-6005 as a promising candidate for further development as an antiviral drug for the treatment of IAV infection and provide chemical-level details for inhibitor optimization.
DescriptionHybrid open access
Persistent Identifierhttp://hdl.handle.net/10722/299294
ISSN
2023 Impact Factor: 4.0
2023 SCImago Journal Rankings: 1.378
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYang, F-
dc.contributor.authorPang, B-
dc.contributor.authorLai, KK-
dc.contributor.authorCheung, NN-
dc.contributor.authorDai, J-
dc.contributor.authorZhang, W-
dc.contributor.authorZhang, J-
dc.contributor.authorChan, KH-
dc.contributor.authorChen, H-
dc.contributor.authorSze, KH-
dc.contributor.authorZhang, H-
dc.contributor.authorHao, Q-
dc.contributor.authorYang, D-
dc.contributor.authorYuen, KY-
dc.contributor.authorKao, RY-
dc.date.accessioned2021-05-10T06:59:46Z-
dc.date.available2021-05-10T06:59:46Z-
dc.date.issued2021-
dc.identifier.citationJournal of Virology, 2021, v. 95 n. 9, p. article no. e01432-20-
dc.identifier.issn0022-538X-
dc.identifier.urihttp://hdl.handle.net/10722/299294-
dc.descriptionHybrid open access-
dc.description.abstractInfluenza A viruses (IAVs) continue to pose an imminent threat to humans due to annual influenza epidemic outbreaks and episodic pandemics with high mortality rates. In this context, the suboptimal vaccine coverage and efficacy, coupled with recurrent events of viral resistance against a very limited antiviral portfolio, emphasize an urgent need for new additional prophylactic and therapeutic options, including new antiviral targets and drugs with new mechanisms of action to prevent and treat influenza virus infection. Here, we characterized a novel influenza A virus nucleoprotein (NP) inhibitor, FA-6005, that inhibited a broad spectrum of human pandemic and seasonal influenza A and B viruses in vitro and protects mice against lethal influenza A virus challenge. The small molecule FA-6005 targeted a conserved NP I41 domain and acted as a potentially broad, multimechanistic anti-influenza virus therapeutic since FA-6005 suppressed influenza virus replication and perturbed intracellular trafficking of viral ribonucleoproteins (vRNPs) from early to late stages. Cocrystal structures of the NP/FA-6005 complex reconciled well with concurrent mutational studies. This study provides the first line of direct evidence suggesting that the newly identified NP I41 pocket is an attractive target for drug development that inhibits multiple functions of NP. Our results also highlight FA-6005 as a promising candidate for further development as an antiviral drug for the treatment of IAV infection and provide chemical-level details for inhibitor optimization.-
dc.languageeng-
dc.publisherAmerican Society for Microbiology. The Journal's web site is located at http://jvi.asm.org/-
dc.relation.ispartofJournal of Virology-
dc.rightsJournal of Virology. Copyright © American Society for Microbiology.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectinfluenza-
dc.subjectnucleoprotein-
dc.subjectsmall-molecule inhibitor-
dc.titleDiscovery of a Novel Specific Inhibitor Targeting Influenza A Virus Nucleoprotein with Pleiotropic Inhibitory Effects on Various Steps of the Viral Life Cycle-
dc.typeArticle-
dc.identifier.emailChan, KH: chankh2@hkucc.hku.hk-
dc.identifier.emailChen, H: hlchen@hku.hk-
dc.identifier.emailSze, KH: khsze@hku.hk-
dc.identifier.emailHao, Q: qhao@hku.hk-
dc.identifier.emailYang, D: yangdan@hku.hk-
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hk-
dc.identifier.emailKao, RY: rytkao@hkucc.hku.hk-
dc.identifier.authorityChan, KH=rp01921-
dc.identifier.authorityChen, H=rp00383-
dc.identifier.authoritySze, KH=rp00785-
dc.identifier.authorityHao, Q=rp01332-
dc.identifier.authorityYang, D=rp00825-
dc.identifier.authorityYuen, KY=rp00366-
dc.identifier.authorityKao, RY=rp00481-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1128/JVI.01432-20-
dc.identifier.pmid33627391-
dc.identifier.pmcidPMC8104107-
dc.identifier.scopuseid_2-s2.0-85104276049-
dc.identifier.hkuros322422-
dc.identifier.volume95-
dc.identifier.issue9-
dc.identifier.spagearticle no. e01432-
dc.identifier.epage20-
dc.identifier.isiWOS:000640382100013-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats